Following a decade of successfully shaping market leaders across the rapidly evolving animal health market, Fidelio Capital AB (Fidelio) today announced the formation of Vimian – a global and diversified group of innovation-driven companies operating in four fast-growing animal health verticals. Headquartered in Stockholm, Sweden, Vimian and its family of companies serve more than 15,000 customers in +70 countries, employ over 400 people and have a combined turnover of approximately EUR 140 million.
Vimian and its family of companies cover four essential areas within animal health; Specialty Pharma, Diagnostics, Veterinary Services and MedTech. All companies share a passion for making a positive impact through improved animal health, by delivering solutions, products and services to animals and veterinary professionals around the world.
“By establishing Vimian, we are creating a global platform with a clear ambition to lead the ongoing transformation of the animal health market. With Vimian, we are bringing together some of the most innovative, high-quality and entrepreneurial businesses under one umbrella, to create a uniquely diversified proposition of products and services across four fast-growing animal health verticals”, says Gabriel Fitzgerald, Founder and CEO of Fidelio.
The first building block of Vimian was laid in 2015, when Fidelio invested in what was to become Nextmune, Vimian’s Specialty Pharma division. Since then, Fidelio has continued to partner with entrepreneurs, management teams and owners of market leading businesses within Diagnostics (Indical Bioscience), Veterinary Services (VetFamily) and MedTech (Movora). To date, 20 companies have joined the Vimian platform on its ongoing journey towards improved animal health for better lives.
“With Vimian, we combine the strengths and capabilities of a global group with the intimacy, speed and creativity of an owner-led business. By sharing knowledge, insights and resources across our family of businesses, we create an unmatched opportunity to accelerate innovation, talent acquisition and growth. Together, we are able to reach over 15,000 veterinary clinics and 1,500 labs globally, with exceptional science and technology throughout our four areas. We all share a passion for making a positive impact through improved animal health, and I look forward to an exciting journey ahead with the entire Vimian team”, says Dr. Fredrik Ullman, CEO of Vimian (former CEO of Indical Bioscience).
Vimian Group AB (publ) (“Vimian”, the “Group” or the “Company”), a global, fast-growing and innovation-driven animal health business, offering products, services and solutions to veterinary professionals, labs and pet parents around the world, today announces the listing of and commencementRead more
Vimian Group AB (publ), a global, fast-growing and innovation-driven animal health business, offering products, services and solutions to veterinary professionals, labs and pet parents around the world, announces its intention to carry out a private placement of shares in theRead more
Indical has acquired the Svanova product portfolio from Boehringer Ingelheim. Through the acquisition, Indical becomes the exclusive provider of Svanova’s veterinary testing products, which include around 25 livestock ELISA assays. Svanova arose out of the Swedish Veterinary Institute, a pioneerRead more